MedTrace Logo

Weight Management Intervention for Youth and Young Adults With Autism Spectrum Disorder

NCT03865719 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2022-04-06

No results posted yet for this study

Summary

Psychotropic medications are the first-line treatment across several diagnostic categories encompassing severe mood disturbances and behavioral problems. The use of Second Generation Antipsychotics (SGAs) has increased in children with Autism Spectrum Disorder (ASD) in the last decade. However, SGAs are associated with serious metabolic side effects in youth that include cardiovascular disease, hypertension, and diabetes mellitus. This makes the public health impact of treating medication-induced metabolic disturbances almost as important as treating the mental illness itself. Improving health and reducing premature mortality in people with severe mental illness, the investigators propose to provide early weight management prevention, delivered by clinicians, for youth starting SGAs in order to target common modifiable health risk factors in the developmental process. This study will provide an urgently needed practical model for integrating weight management into academic- and community-based autism care.

Conditions

Interventions

BEHAVIORAL

Healthy Habits for Life

Healthy Habits for Life: 11-session, 6 month, one-on-one, dietician-lead weight management manualized treatment.

Sponsors & Collaborators

  • Massachusetts General Hospital

    collaborator OTHER

  • University of Pittsburgh

    lead OTHER

Principal Investigators

  • Dana L Rofey, PhD · University of Pittsburgh

  • Benjamin L Handen, PhD, BCBA-D · University of Pittsburgh

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
8 Years
Max Age
26 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-08-07
Primary Completion
2021-03-15
Completion
2021-12-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03865719 on ClinicalTrials.gov